Armata receives FDA Fast Track for AP-SA02 phage therapy for S. aureus bacteremia

Armata Pharmaceuticals, Inc.

• Fast Track designation enables rolling BLA review and potential Accelerated Approval and Priority Review.
• Phase 3 superiority study anticipated to begin in H2 2026.
• AP-SA02 targets complicated bacteremia from MSSA and MRSA.
• FDA designation underscores unmet need in severe, often deadly S. aureus infections.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.